

Dr. Ph.D. Yang Zijiang
Research Fellow
Biomedical Engineering and Stem Cell Bioengineering)
Harvard-MIT Health Sciences and Technology
Harvard Medicine School & MIT
Cambridge, MA, USA

Education

2010 – 2013	**Research Fellow (Biomedical Engineering and Stem Cell Bioengineering)** Harvard-MIT Health Sciences and Technology Harvard Medicine School & MIT, Cambridge, MA, US
2007 – 2010	**Ph.D. (stem cell therapy for neovascularization)** Institute of Clinical Research (DKF), University of Bern, Bern, Switzerland
2005 – 2007	**M.Sc. (molecular cell biology)** Uppsala University, Uppsala, Sweden Karolinska Institutet, Stockholm, Sweden
2003 – 2004	**Poly/Monoclonal Antibody Researcher** Shanghai Genomics, Inc., National Human Genome Centre at Shanghai, China
1999 – 2003	***B.Eng. (Bioengineering)*** Shanghai Jiao Tong University, China

Professional Experience

2015 -	**Hangzhou Life Perfusor Medical, Hangzhou, China** Co-Founder
2015 - 2016	**Velox Biosystems, U.S.** Co-Founder
2014 -	**Shanghai Jiao Tong University** Researcher

Professional Affiliations and Activity:

2018 - - IOPS, International Organ Protection Society,
Co-Founder, Member of Committee International

Awards

2003	Best B.Eng. thesis, Shanghai Jiao Tong University
2008	Department of Clinical Research Day, University of Bern Best Poster in Medical Student Section
2010	Pfizer Research Price (Stiftung Pfizer Forschungs-Preis), Switzerland Cardiovascular, Urology and Nephrology Section
2010	Fellowship for prospective researchers, Swiss National Science Foundation Nr. PBBEP3_133508
2010	Swiss Society of Angiology (Schweizerische Gesellschaft für Angiologie), Switzerland
2010	Swiss Angiology Price (Schweizerischer Angiologiepreis 2010)
2010	Chinese Government Award for Outstanding Self-Financed Students Abroad

Patents

12 issued patents in China

Publications

Hjortsberg L, Pokrovskaja K, Björklund A, **Yang Z**, Arulampalam V, Grandér D. Importance of STAT-signaling in interferon-alpha induced apoptosis. 2007. ISBN: 978-91 -7357-186-9.

Yang Z. The role of endothelial progenitor cell in therapeutic neovascularization. University of Bern, Switzerland; 2010. (Ph.D. thesis)

Di Santo S, Diehm N, Ortmann J, Voelzmann J, **Yang Z**, Keo HK, Baumgartner I, Kalka C. Oxidaized low density lipoproteins (oxLDL) impairs endothelial progenitor cell function by downregulation of E-selectin and integrin αvβ5.
Biochem Biophys Res Commun. 2008; 373(4):528:532.

Di Santo S*, **Yang Z***, Wyler von Ballmoos M, Voelzmann J, Diehm N, Baumgartner I, Kalka C. Novel cell-free strategy for therapeutic angiogenesis: In vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One. 2009 May 21; 4(5):e5643.

Yang Z, von Ballmoos MW, Diehm N, Baumgartner I, Kalka C, Di Santo S. Call for a reference model of chronic hind limb ischemia to investigate therapeutic angiogenesis. Vascular Pharmacology. 51 (2009) 268–274.

von Ballmoos MW*, **Yang Z***, Diehm N, Völzmann J, Baumgartner I, Kalka C, Di Santo S. Endothelial progenitor cells induce a phenotype shift in differentiated endothelial cells towards PDGF-BB sensitivity and increased angiogenesis. J Vasc Res 2009; 46:5-60.

Yang Z, von Ballmoos MW, Faesselr D, Voelzmann J, Ortmann J, Diehm N, Kalka-Moll W, Baumgartner I, DiSanto S, Kalka C. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothelial cells. Atherosclerosis. 2010 Jul; 211(1):103-109.

Ortmann J, Veith M, Zingg S, Di Santo S, Traupe T, **Yang Z**, Völzmann J, Dubey R, Christen S, Baumgartner I. Estrogen Receptor-{alpha} But Not -{beta} or GPER Inhibits High Glucose-Induced Human VSMC Proliferation: Potential Role of ROS and ERK. J Clin Endocrinol Metab. 2011 Jan; 96(1):220-8.

Wyler von Ballmoos M*, **Yang Z***, Völzmann J, Baumgartner I, Kalka C, Di Santo S. Endothelial Progenitor Cells Induce a Phenotype Shift in Differentiated Endothelial Cells towards PDGF/PDGFRβ Axis-Mediated Angiogenesis. PLoS One. 2010 Nov 24; 5(11):e14107.

Yang Z, Di Santo S, Kalka C. Current developments in the use of stem cell for therapeutic neovascularization: Is the future therapy "cell-free"? Swiss Med Wkly. 2010 Dec 17; 140:w13130.

Gajanayake T, Olariu R, Leclère FM, Dhayani A, **Yang Z**, Bongoni AK, Banz Y, Constantinescu MA, Karp JM, Vemula PK, Rieben R, Vögelin E. *A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. (Sci Transl Med. 2014 Aug 13; 6(249):249ra110.).*

Teo GS, **Yang Z**, Carman CV, Karp JM, Lin CP. *Intravital imaging of mesenchymal stem cell trafficking and association with platelets and neutrophils. (Stem Cells. 2015 Jan; 33(1):265-77.).*

Levy O, Mortensen LJ, Boquet G, Tong Z, Perrault C, Benhamou B, Zhang J, Stratton T, Han E, Safaee H, Musabeyezu J, **Yang Z**, Multon MC, Rothblatt J, Deleuze JF, Lin CP, Karp JM. *A small-molecule screen for enhanced homing of systemically infused cells. (Cell Rep. 2015 Mar 3; 10(8):1261-1268.)*

Yang Z, Concannon J, Ng KS, Seyb K, Mortensen LJ, Ranganath S, Gu F, Levy O, Tong Z, Martyn K, Zhao W, Lin CP, Glicksman MA, Karp JM. *Tetrandrine identified in a small molecule screen to activate mesenchymal stemcells for enhanced immunomodulation. (Sci Rep. 2016 Jul 26; 6:30263.)*